<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119077</url>
  </required_header>
  <id_info>
    <org_study_id>18752</org_study_id>
    <secondary_id>2016-003520-23</secondary_id>
    <nct_id>NCT03119077</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in a single center, double-blind with 6 dose escalation groups
      to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of
      BAY1161116.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study early terminated due to lower drug exposure
  </why_stopped>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">September 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of TEAEs</measure>
    <time_frame>5 weeks</time_frame>
    <description>TEAEs: treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>5 weeks</time_frame>
    <description>TEAEs: treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of BAY1161116</measure>
    <time_frame>5 weeks</time_frame>
    <description>AUC: Area under the concentration vs. time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BAY1161116</measure>
    <time_frame>5 weeks</time_frame>
    <description>Cmax: maximum observed drug concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>BAY1161116</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose steps 1 to 6 of BAY1161116 (increasing dose levels)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Dose 1 to 6 of BAY 1161116</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1161116</intervention_name>
    <description>Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food</description>
    <arm_group_label>BAY1161116</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Redosing of BAY1161116/placebo at dose group 1 together with itraconazole</description>
    <arm_group_label>BAY1161116</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female postmenopausal subjects

          -  Age: 45 to 65 years (inclusive)

          -  Body mass index (BMI) : ≥18 and ≤30 kg/m²

          -  Non-smoker for 3 months (former smokers who quit smoking &gt;3 months before the first
             study drug administration may be included)

        Exclusion Criteria:

          -  Incomplete recovery from pre-existing disease for which it can be assumed that the
             absorption, distribution, excretion,and effect of the study drugs will not be normal

          -  Any use of systemic or topically active medication or herbal remedies, prescription or
             non-prescription, from screening to the first drug administration (occasional use of
             paracetamol or ibuprofen is permissible)

          -  Any severe disease within the last 4 weeks prior to the first study drug
             administration

          -  History of orthostatic hypotension, fainting spells, blackouts

          -  Any malignant tumor and history thereof

          -  Any other medical condition which, at the discretion of the investigator, would make
             study participation unadvisable

          -  Any clinically relevant finding at the physical- and gynecological examinations

          -  Allergy, hypersensitivity, or non-allergic drug reactions to any excipient of the IMP
             or reference/interaction product

          -  Regular alcohol consumption equivalent to &gt;20 g alcohol per day

          -  Urine screen positive for any drug or cotinine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

